Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person's ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.

Scope of the Report:

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

The global Major Depressive Disorder (MDD) market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Major Depressive Disorder (MDD).

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

This report studies the Major Depressive Disorder (MDD) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Major Depressive Disorder (MDD) market by product type and applications/end industries.

Market Segment by Companies, this report covers

Pfizer

GlaxoSmithKline

Merck

AstraZeneca

Eli Lily

Johnson & Johnson

Forest Laboratories

Sanofi-Aventis

H. Lundbeck

Bristol-Myers Squibb

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Antidepressant Drugs

SSRIs

SNRIs

Benzodiazepines

Others

Market Segment by Applications, can be divided into

Hospitals

Clinics

Others

Table of Contents

1 Major Depressive Disorder (MDD) Market Overview

1.1 Product Overview and Scope of Major Depressive Disorder (MDD)

1.2 Classification of Major Depressive Disorder (MDD) by Types

1.2.1 Global Major Depressive Disorder (MDD) Revenue Comparison by Types (2017-2023)

1.2.2 Global Major Depressive Disorder (MDD) Revenue Market Share by Types in 2017

1.2.3 Antidepressant Drugs

1.2.4 SSRIs

1.2.5 SNRIs

1.2.6 Benzodiazepines

1.2.7 Others

1.3 Global Major Depressive Disorder (MDD) Market by Application

1.3.1 Global Major Depressive Disorder (MDD) Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Global Major Depressive Disorder (MDD) Market by Regions

1.4.1 Global Major Depressive Disorder (MDD) Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Major Depressive Disorder (MDD) Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Major Depressive Disorder (MDD) Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Major Depressive Disorder (MDD) Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Major Depressive Disorder (MDD) Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Major Depressive Disorder (MDD) Status and Prospect (2013-2023)

1.5 Global Market Size of Major Depressive Disorder (MDD) (2013-2023)

2 Manufacturers Profiles

2.1 Pfizer

2.1.1 Business Overview

2.1.2 Major Depressive Disorder (MDD) Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Pfizer Major Depressive Disorder (MDD) Revenue, Gross Margin and Market Share (2016-2017)

2.2 GlaxoSmithKline

2.2.1 Business Overview

2.2.2 Major Depressive Disorder (MDD) Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 GlaxoSmithKline Major Depressive Disorder (MDD) Revenue, Gross Margin and Market Share (2016-2017)

2.3 Merck

2.3.1 Business Overview

2.3.2 Major Depressive Disorder (MDD) Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Merck Major Depressive Disorder (MDD) Revenue, Gross Margin and Market Share (2016-2017)

2.4 AstraZeneca

2.4.1 Business Overview

2.4.2 Major Depressive Disorder (MDD) Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 AstraZeneca Major Depressive Disorder (MDD) Revenue, Gross Margin and Market Share (2016-2017)

2.5 Eli Lily

2.5.1 Business Overview

2.5.2 Major Depressive Disorder (MDD) Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Eli Lily Major Depressive Disorder (MDD) Revenue, Gross Margin and Market Share (2016-2017)

2.6 Johnson & Johnson

2.6.1 Business Overview

2.6.2 Major Depressive Disorder (MDD) Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Johnson & Johnson Major Depressive Disorder (MDD) Revenue, Gross Margin and Market Share (2016-2017)

2.7 Forest Laboratories

2.7.1 Business Overview

2.7.2 Major Depressive Disorder (MDD) Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Forest Laboratories Major Depressive Disorder (MDD) Revenue, Gross Margin and Market Share (2016-2017)

2.8 Sanofi-Aventis

2.8.1 Business Overview

2.8.2 Major Depressive Disorder (MDD) Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Sanofi-Aventis Major Depressive Disorder (MDD) Revenue, Gross Margin and Market Share (2016-2017)

2.9 H. Lundbeck

2.9.1 Business Overview

2.9.2 Major Depressive Disorder (MDD) Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 H. Lundbeck Major Depressive Disorder (MDD) Revenue, Gross Margin and Market Share (2016-2017)

2.10 Bristol-Myers Squibb

2.10.1 Business Overview

2.10.2 Major Depressive Disorder (MDD) Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Bristol-Myers Squibb Major Depressive Disorder (MDD) Revenue, Gross Margin and Market Share (2016-2017)

3 Global Major Depressive Disorder (MDD) Market Competition, by Players

3.1 Global Major Depressive Disorder (MDD) Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Major Depressive Disorder (MDD) Players Market Share

3.2.2 Top 10 Major Depressive Disorder (MDD) Players Market Share

3.3 Market Competition Trend

4 Global Major Depressive Disorder (MDD) Market Size by Regions

4.1 Global Major Depressive Disorder (MDD) Revenue and Market Share by Regions

4.2 North America Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

4.3 Europe Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

4.5 South America Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

5 North America Major Depressive Disorder (MDD) Revenue by Countries

5.1 North America Major Depressive Disorder (MDD) Revenue by Countries (2013-2018)

5.2 USA Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

5.3 Canada Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

5.4 Mexico Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

6 Europe Major Depressive Disorder (MDD) Revenue by Countries

6.1 Europe Major Depressive Disorder (MDD) Revenue by Countries (2013-2018)

6.2 Germany Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

6.3 UK Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

6.4 France Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

6.5 Russia Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

6.6 Italy Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Major Depressive Disorder (MDD) Revenue by Countries

7.1 Asia-Pacific Major Depressive Disorder (MDD) Revenue by Countries (2013-2018)

7.2 China Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

7.3 Japan Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

7.4 Korea Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

7.5 India Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

8 South America Major Depressive Disorder (MDD) Revenue by Countries

8.1 South America Major Depressive Disorder (MDD) Revenue by Countries (2013-2018)

8.2 Brazil Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

8.3 Argentina Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

8.4 Colombia Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Major Depressive Disorder (MDD) by Countries

9.1 Middle East and Africa Major Depressive Disorder (MDD) Revenue by Countries (2013-2018)

9.2 Saudi Arabia Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

9.3 UAE Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

9.4 Egypt Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

9.5 Nigeria Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

9.6 South Africa Major Depressive Disorder (MDD) Revenue and Growth Rate (2013-2018)

10 Global Major Depressive Disorder (MDD) Market Segment by Type

10.1 Global Major Depressive Disorder (MDD) Revenue and Market Share by Type (2013-2018)

10.2 Global Major Depressive Disorder (MDD) Market Forecast by Type (2018-2023)

10.3 Antidepressant Drugs Revenue Growth Rate (2013-2023)

10.4 SSRIs Revenue Growth Rate (2013-2023)

10.5 SNRIs Revenue Growth Rate (2013-2023)

10.6 Benzodiazepines Revenue Growth Rate (2013-2023)

10.7 Others Revenue Growth Rate (2013-2023)

11 Global Major Depressive Disorder (MDD) Market Segment by Application

11.1 Global Major Depressive Disorder (MDD) Revenue Market Share by Application (2013-2018)

11.2 Major Depressive Disorder (MDD) Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Clinics Revenue Growth (2013-2018)

11.5 Others Revenue Growth (2013-2018)

12 Global Major Depressive Disorder (MDD) Market Size Forecast (2018-2023)

12.1 Global Major Depressive Disorder (MDD) Market Size Forecast (2018-2023)

12.2 Global Major Depressive Disorder (MDD) Market Forecast by Regions (2018-2023)

12.3 North America Major Depressive Disorder (MDD) Revenue Market Forecast (2018-2023)

12.4 Europe Major Depressive Disorder (MDD) Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Major Depressive Disorder (MDD) Revenue Market Forecast (2018-2023)

12.6 South America Major Depressive Disorder (MDD) Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Major Depressive Disorder (MDD) Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source

List of Tables and Figures

Figure Major Depressive Disorder (MDD) Picture

Table Product Specifications of Major Depressive Disorder (MDD)

Table Global Major Depressive Disorder (MDD) and Revenue (Mil